2016
DOI: 10.18632/oncotarget.7746
|View full text |Cite
|
Sign up to set email alerts
|

The afatinib resistance of in vivo generated H1975 lung cancer cell clones is mediated by SRC/ERBB3/c-KIT/c-MET compensatory survival signaling

Abstract: We generated afatinib resistant clones of H1975 lung cancer cells by transient exposure of established tumors to the drug and collected the re-grown tumors. Afatinib resistant H1975 clones did not exhibit any additional mutations in proto-oncogenes when compared to control clones. Afatinib resistant H1975 tumor clones expressed less PTEN than control clones and in afatinib resistant clones this correlated with increased basal SRC Y416, ERBB3 Y1289, AKT T308 and mTOR S2448 phosphorylation, decreased expression … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

4
43
3

Year Published

2016
2016
2022
2022

Publication Types

Select...
6
2

Relationship

3
5

Authors

Journals

citations
Cited by 42 publications
(50 citation statements)
references
References 16 publications
4
43
3
Order By: Relevance
“…The UPR is an ER stress‐activated signaling pathway that modifies cell proliferation and survival and plays an important role in HCC development . During ER stress different transcription factors regulate the expression of ER chaperones which are often overexpressed in tumor tissues . Different studies have shown that the UPR is regulated by the circadian clock .…”
Section: Discussionmentioning
confidence: 99%
“…The UPR is an ER stress‐activated signaling pathway that modifies cell proliferation and survival and plays an important role in HCC development . During ER stress different transcription factors regulate the expression of ER chaperones which are often overexpressed in tumor tissues . Different studies have shown that the UPR is regulated by the circadian clock .…”
Section: Discussionmentioning
confidence: 99%
“…Finally, we explored the potential mechanism of acquired resistance to afatinib. Previous studies revealed distinct mechanisms of acquired resistance to afatinib in lung cancer including MET amplification, IGF1R and SRC upregulation, and AKT phosphorylation . In the present study, we observed not only the elevated phosphorylation of AKT/S6 and MEK/ERK/JNK2/p38, but also the enrichment of genes involved in cell cycle pathway in the afatinib‐resistant PDX model.…”
Section: Discussionsupporting
confidence: 74%
“…One of the key observations made in this manuscript and in the recent Booth et al manuscript that examines the biology of the afatinib resistant H1975 cells in greater detail is that afatinib resistant H1975 clones do not exhibit any additional “hotspot” mutations in proto-oncogenes compared to controls that would have been a priori predicted [10]. In the ADOR PDX isolate, again to our surprise, no well described proto-oncogene driving mutation was identified.…”
Section: Discussionmentioning
confidence: 63%
“…Control treated tumors were also isolated when they had a volume of ~500 mm 3 . Of significant note for clonal characterization, the isolated afatinib treated tumor clones’ cells were only growth inhibited by afatinib when cultured in vitro with daily supplementation at concentrations >> 2 μM, and as such these afatinib resistant cells were routinely passaged in a pulsatile fashion between experiments in growth media containing only 1 μM afatinib to maintain the afatinib resistant phenotype but not to promote further selective pressure on drug resistance and thus also did not cause selection of surviving clones due to non-ERBB1/2/4 off-target effects [10]. …”
Section: Methodsmentioning
confidence: 99%